top of page
News, Events and Updates
Search
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
Nov 25, 2025
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
Nov 19, 2025
Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025
Nov 18, 2025
Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX®3-71 Program
Oct 2, 2025
Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
Oct 2, 2025
Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update
Aug 12, 2025
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
May 14, 2025
Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
May 13, 2025
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
May 6, 2025
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
May 1, 2025
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
Apr 23, 2025
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East
Apr 21, 2025
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
Apr 5, 2025
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
Mar 31, 2025
Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference
Feb 24, 2025
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Jan 6, 2025
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
Dec 23, 2024
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024
Dec 2, 2024
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
Oct 31, 2024
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
Oct 17, 2024
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
